Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $12.24 the fair market value on December 30, 2011, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option was effective as of December 30, 2011, and also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin i
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... the Piper Jaffray 26 th Annual Healthcare Conference in ... the Piper Jaffray conference is scheduled for 8:00 am EST (5:00 ... webcast, and the webcast can be accessed via the Investor Relations ... of the webcast will be archived for 30 days on the ...
(Date:11/21/2014)... Nov. 20, 2014 Oxis International, Inc. (OXIS) (OXI.PA) ... election of Anthony J. Cataldo as Chief Executive ... Effective November 19, 2014, Ken Eaton resigned his ... of Directors of Oxis International, Inc. to pursue new opportunities. ... named Chief Executive Officer of Oxis International, Inc. Mr. Cataldo ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... CPHD ) today announced that Robert Kwiatkowski, ... of Infectious Disease Research and Development, reporting to David ... impressive menu of eleven highly regarded Xpert® tests for ... extend our leadership with next-generation products, including a number ...
... BETHLEHEM, Pa., June 22, 2011 In a ... of diazepam (NRL-1) achieved positive clinical results in ... was designed and manufactured at Particle Sciences.  In ... pharmacokinetic profile comparable to that reported in the ...
Cached Medicine Technology:Cepheid Appoints Vice President of Infectious Disease Research & Development 2Cepheid Appoints Vice President of Infectious Disease Research & Development 3Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam) 2
(Date:11/23/2014)... 23, 2014 Locks-Magnetic.com, a notable magnetic ... Moreover, all the new products are available at low ... manager is proud of the new emergency doors. The ... And customers can choose from several colors. All of ... quality emergency door release is not as easy as ...
(Date:11/23/2014)... November 23, 2014 SWAccessControl.com's high quality ... market. Recently, the company has announced its new collection ... offer on these high quality power suppliers. All the ... off. The special offer lasts until Dec. 20, 2014. ... of them have been supporting it for a long ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity doctor ... was recently featured on International Business Times. ... of American Medical Aesthetics & Wellness, also known as ... scholarship to attend an M.D./Ph.D program at University of ... of Chicago, where his field of study was neuro-biochemistry. ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... City, Utah (PRWEB) November 23, 2014 ... health insurance reimbursement for small businesses, announced their ... book, The End of Employer-Provided Health Insurance. ... insurance is the greatest financial risk facing most ... facing U.S. employers, small and large, when it ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2
... active may help to tackle health threats, study says ... large body size, former professional football players aren,t at ... that looked at 201 retired NFL players. , The ... group of men from the population-based Dallas Heart Study ...
... -- The angiotensin system inhibitor irbesartan did not improve outcomes ... left ventricular ejection fraction. -- ... predominantly affects women and older patients; ... therapies is critical. NEW ORLEANS, Nov. 11 An angiotensin ...
... prevention trial on low-dose aspirin in diabetics,Japanese investigators report ... preventing the primary endpoints of all atherosclerotic events,although it ... - Low-dose aspirin was also associated with a reduced ... a subgroup of diabetics who,were over age 65., ...
... highlights:, -- Individually tailored doses of ... month as measured by platelet reactivity,monitoring by ... measures a,patient,s anti-platelet response to clopidogrel., ... bleeding events,between treatment and control groups., ...
... Study highlights:, - In a randomized, double-blind study ... C-reactive protein (hsCRP) greater than or equal to,2, those ... 31 heart attacks,and 33 strokes compared to 68 and ... analysis showed similar findings across gender, race,ethnicity and Framingham ...
... N.J., Nov. 11, 2008) The F.M. Kirby Foundation of ... Nursing at Rutgers, The State University of New Jersey, to ... Jersey residents. , The grant will also fund the work ... and service in the best academic tradition, said Interim Dean ...
Cached Medicine News:Health News:Retired NFL Players Don't Face Greater Heart Risk 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 2Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 4Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 2Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 2Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 4Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 5
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Medicine Products: